All In Biotech

NDA 208277 · Catalyst Pharms

Fycompa

Perampanel · Oral · Noncompetitive AMPA Glutamate Receptor Antagonist

Last checked: Nov 19, 2026Latest source record: May 23, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 29, 2016

Approved uses

3

Original approval plus efficacy supplements

Registered trials

83

18 Phase 3, 6 recruiting

FAERS reports

7,728

6,392 serious, 472 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA ( 5.1 ). These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression ( 5.1 ). Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA ( 5.1 ). Closely monitor patients particularly during the titration period and at higher doses ( 5.1 ). FYCOMPA should be reduced if these symptoms occur and should be discontinued...

What it is approved for

From the label in effect Jan 5, 2024.

FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures FYCOMPA is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures FYCOMPA is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • FYCOMPA · PERAMPANEL 0.5MG/ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Perampanel" as an intervention, any sponsor and status, largest first.

All 83 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure1,171
  • drug ineffective1,129
  • off label use830
  • somnolence525
  • aggression504
  • dizziness408
  • epilepsy377
  • status epilepticus350
  • drug interaction343
  • multiple-drug resistance332
  • fatigue316
  • irritability253

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20128
201316
2014183
2015275
2016332
2017455
2018572
2019705
2020664
2021779
2022668
2023765
2024908
2025884
2026514

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fycompa (Perampanel)

2024 spending

$75.7M

Beneficiaries

6,558

59,762 claims

Per beneficiary

$11,544

$37.61 per unit

View as table
YearSpending
2020$51,630,237
2021$57,404,778
2022$65,621,224
2023$72,036,496
2024$75,702,972

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 161 on PubMed

Sponsor: Catalyst Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.